Ask AI
ProCE Banner Activity

FLAURA2: Final Overall Survival of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC

Conference Coverage
Slideset

Final overall survival analysis of the phase III FLAURA2 trial of first-line osimertinib plus chemotherapy demonstrated significantly improved overall survival vs osimertinib alone in patients with EGFR-mutated advanced NSCLC.

Released: November 13, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.